Terapia choroby Parkinsona stanowi wyzwanie z uwagi na stopniową progresję objawów ruchowych, występowanie objawów pozamotorycznych oraz możliwe efekty uboczne leczenia. W niniejszym artykule zawarto najnowsze zalecenia dotyczące farmakoterapii choroby oraz jej powikłań. Ze względu na dostępne strategie lecznicze konieczne jest, by wybór każdorazowo został dokonany indywidualnie, z uwzględnieniem szeregu objawów stwierdzanych u chorego.
Autor: lek. Izabela Meisner-Kramarz
Data publikacji: 2015-02-06
Źródło: Lek w Polsce 01/2015
Słowa kluczowe: choroba Parkinsona, farmakoterapia, lewodopa, leczenie choroby Parkinsona, agoniści dopaminy, amantadyna, leki cholinolityczne.
1. EFNS/MDS-ES Guidelines: Summary of the recommendations of the EFNS/ MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013 Jan; 20(1): 5-15.
2. Sławek J, Friedman A, Bogucki A, w wsp: Choroba Parkinsona i inne zaburzenia ruchowe- część 1. Via Medica 2011; 1; 175-212.
3. Whone AL, Watts RL, Stoessl AJ i wsp: REAL-PET Study Group. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.
4. Gertel WH, Wolters E, Sampaio C i wsp: Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord 2006; 21: 343-353.
5. Holloway RG, Shoulson I, Fahn S i wsp: Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. The Parkinson Study Group. Arch Neurol 2004; 61: 1044-1053.
6. Kulisevsky J, Lopez-Villegas D, Garcia-Sanchez C i wsp: A sixmonth study of pergolide and levodopa in de novo Parkinson’s disease patients. Clin Neuropharmacol 1998; 21: 358-362.
7. Rinne UK, Bracco F, Chouza C i wsp: Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The KD 5009 Collaborative Study Group. Neurology 1997; 48: 363-368.
8. Koller WC, Hutton JT, Tolosa E i wsp: Immediate- release and controlled- release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/ Levodopa Study Group. Neurology 1999; 53: 1012-1019.
9. Goetz CG, Tanner CM, Shannon KM I wsp: Controlled-release carbidopa/levodopa (CR4- Sinemet) in Parkinson’s disease patients with and without motor fluctuations. Neurology 1988; 38: 1143-1146.
10. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364-1371.
11. Myllyla VV, Sotaniemi KA, Vourinen JA i wsp: Selegiline as initial treatment In de novo parkinsonian patients. Neurology 1992; 42: 339-343.
12. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937-1943.
13. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561-566.
14. Teravainen H. Selegiline in Parkinson’s disease. Acta Neurol Scand 1990; 81: 333-336.
15. Allain H, Pollak P, Neukirch HC. Symptomatic effect of Selegiline in de novo Parkinsonian patients. The Grench Selegiline Multicenter Trial. Mov Disord 1993; 8 (Suppl.1): 536-540.
16. Palhagen S, Heinonen EH, Hagglund J i wsp: Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998; 51: 520-525.
17. Olanow CW, Rascol O, Hauser R I wsp: A doubleblind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009; 361: 1268-1278.
18. Begamasco B, Frattola L, Muratorio A i wsp: Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebocontrolled study. Acta Neurol Scand 2000; 101: 372-380.real
19. Barone P, Bravi D, Bermejo-Pareja F I wsp: Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999; 53: 573-579.
20. Shannon KM, Bennett JP Jr, Friedman HJ. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s diseae. The PramipexoleStudy Group. Neurology 1997; 49: 724-728.
21. Adler CH, Sethi KD, Hauser RA i wsp: Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 1997; 49: 393-399.
22. Rascol O, Dubois B, Caldas AC i wsp: Early piribedil monotherapy of Parkinson’s disease: a planned seven-month report of the REGAIN-study. The Parkinson REGAIN Study Group. Mov Disord 2006; 21: 2110-2115.
23. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 2003; 60: 1721-1728.
24. RInne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 1989; 39: 336-339.
25. Riopelle RJ. Bromocriptine and the clinical spectrum of Parkinson’s disease. Can J Neurol Sci 1987; 14: 455-459.
26. RInne UK, Bracco F, Chouza C i wsp: Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a doubleblind levodopa controlled trial. The PKD 5009 Study Group. Drugs 1998; 55 (Suppl.1): 23-30.
27. Parkes JD, Baxter RC, Marsde CD, Rees JE. Comparative trial of benzhexol, amantadine and levodopa in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1974; 37: 422-426.
28. Cooper JA, Sagar HJ, Doherty SM i wsp: Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain 1992; 115(Pt6): 1701-1725.
29. Levine CB, Fahrbach KR, Siderowf AD i wsp: Diagnosis and treatment of Parkinson’s disease: a systematic review of the literature. Evid Rep Technol Assess (Summ) 2003; 57: 1-4.
30. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001; 56: S1-S88.
31. Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord 2005; 20 (Suppl. 11): S11-S16.
32. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000; 284: 1931-1938.
33. Hauser RA, Rascol O, Korczyn AS i wsp: Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007; 22: 2409-2417.
34. Watts RL, Lyons KW, Pahwa R i wsp: Onset of dyskinesias with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord 2010; 25: 858-866.
35. Savery F. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson’s disease. Dis Nerv Syst 1977; 38: 605-608.
36. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev 2003; 2: CD003735.
37. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 2005; 20, 1255-1263.
38. Aarsland D, Andersen K, Larsen JP i wsp: Prevalence and characteristics of dementia in Parkinson disease: and 8-year prospective study. Arch neurol 2003; 60: 387-392.
39. Emre M, Aarsland D, Albanese A i wsp: Rivastigmine for dementia associated ith Parkinson’s disease. N Engl J Med 2004; 351: 2509-2518.
40. Leroi I, Brandt J, Reich SG i wsp: Randomized placebo-controlled trial of donepezil In cognitive impairment In Parkinson’s disease. Int J Geriatr Psychiatry 2004; 19: 1-4.
41. Litvinenko IV, Odinak MM, Mogil’naya VI i wsp: Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol 2008; 38: 937-945.
42. Fenelon G, Mahieux F, Huon R i wsp: Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123(Pt 4): 733-745.
43. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 1999; 340: 757-763.
44. Morgante L, Epifanio A, Spina E I wsp: Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27: 153-156.
45. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with parkinon’s disease: a case series. Curr med Res Opin 2002; 18: 258-264.
46. Cunnings JL. Depression an Parkinson’s disease: a review. Am J Psychiatry 1992; 149: 443-454.
47. Rektorova I, Rektor I, Bares M i wsp: Pramipexole and pergolide in the treatment of depression In Parkinson’s disease: national multicentre prospective randomized study. Eur J Neurol 2003; 10: 399-406.
48. Wientraub D, Morales KH, Moberg PJ I wsp: Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov Disord 2005; 20: 1161-1169.
49. Jankovic J, Gilden JL, Hiner BC i wsp: Neurogenic orthostatic hypotension: a double- blind, placebo-controlled study with midodrine. Am J Med 1993; 95: 38-48.
50. Hoen MM. Levodopa-induced postural hypotension. Treatment with fludrocortisones. Arch Neurol 1975; 32: 50-51.
51. Benson GS, Raezer DM, Andrson JR i wsp: Effect of levodopa on urinary bladder. Urology 1976; 7: 24-28.
52. Winge K, Werdelin LM, Nielsen KK i wsp: Effects of dopaminergic treatment on bladder function in Parkinson’s disease. Neurourol Urodyn 2004; 23: 689-696.
W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki.
Sprawdź więcej ustawień plików cookie, aby zarządzać swoimi preferencjami.
Więcej informacji na temat plików cookie i przechowywania danych można znaleźć w naszej Polityce Prywatności.W celu ulepszenia zawartości naszej strony internetowej oraz dostosowania jej do Państwa osobistych preferencji, wykorzystujemy pliki cookies przechowywane na Państwa urządzeniach. Kontrolę nad plikami cookies można uzyskać poprzez ustawienia przeglądarki internetowej.